Trejo v. Johnson & Johnson Consumer CA2/4

CourtCalifornia Court of Appeal
DecidedAugust 28, 2025
DocketB324219
StatusUnpublished

This text of Trejo v. Johnson & Johnson Consumer CA2/4 (Trejo v. Johnson & Johnson Consumer CA2/4) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Trejo v. Johnson & Johnson Consumer CA2/4, (Cal. Ct. App. 2025).

Opinion

Filed 8/28/25 Trejo v. Johnson & Johnson Consumer CA2/4 NOT TO BE PUBLISHED IN THE OFFICIAL REPORTS

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION FOUR

CHRISTOPHER TREJO, B324219 (Los Angeles County Plaintiff and Appellant, Super. Ct. No. YC058023)

v.

JOHNSON & JOHNSON CONSUMER, INC.,

Defendant and Respondent.

APPEAL from an order of the Superior Court of Los Angeles County, Mary Ann Murphy, Judge. Affirmed. Niddrie Addams Fuller Singh, Rupa G. Singh, for Plaintiff and Appellant. O’Melveny & Myers, Amy J. Laurendeau, Charles C. Lifland, and Carlos M. Lazatin, for Defendant and Respondent. In 2008, Christopher Trejo commenced this action against Johnson & Johnson Consumer Inc. (Johnson & Johnson) for negligence and products liability claims after taking Motrin, an over-the-counter ibuprofen medication. The matter proceeded to trial in 2011 and resulted in a $48 million verdict in Trejo’s favor. Johnson & Johnson appealed. In 2017, this court reversed the judgment and remanded the matter for a limited retrial. In July 2022, Johnson & Johnson filed a motion to dismiss the action for Trejo’s failure to bring the matter to retrial within three years under the mandatory dismissal statutes (Code Civ. Proc., § 583.320 et seq.)1 The court granted the motion. On appeal, Trejo contends the lower court abused its discretion by refusing to toll or exclude from its calculation of the retrial deadline periods in which the court (1) unilaterally continued a pretrial hearing; (2) considered three failed statements of disqualification filed by Trejo; and (3) engaged in other “business and vacation.” We affirm.

FACTUAL AND PROCEDURAL BACKGROUND A. The Complaint, Trial, and Direct Appeal In 2005, Trejo took Motrin, a medication manufactured and sold by Johnson & Johnson’s subsidiary, McNeil Consumer Healthcare (McNeil). Trejo suffered a reaction from the medication in the form of a rare skin disease called Stevens- Johnson Syndrome (SJS) and the more severe variant called Toxic Epidermal Necrolysis (collectively SJS/TEN). (Trejo v. Johnson & Johnson (2017) 13 Cal.App.5th 110, 116 (Trejo I).)

1 Subsequent unspecified references to statutes are to the Code of Civil Procedure.

2 Trejo commenced this lawsuit and the matter proceeded to trial in 2011 on claims of strict liability and negligent failure to warn of skin-related symptoms associated with SJS/TEN, as well as strict liability and negligent design defect based on the failure to sell an allegedly safer product called dexibuprofen. (Trejo I, supra, 13 Cal.App.5th at pp. 116, 123, 142.) By special verdict, the jury found McNeil liable for negligent failure to warn, negligent design defect, and strict liability design defect under the consumer expectation test. Under the same test, the jury found Johnson & Johnson liable for strict liability design defect. Trejo was awarded $39,401,210 in economic, noneconomic, and punitive damages against McNeil and $8,791,670 in punitive damages against Johnson & Johnson. (Id. at p. 123.) In 2017, a different panel of this court issued a lengthy decision reversing the judgment and remanding the matter for retrial, limited to claims for strict liability and negligent failure to warn.2 (Trejo I, supra, 13 Cal.App.5th at p. 161.) Trejo’s petitions for rehearing and review were denied in July and October 2017, respectively. (Ibid.; S243672.)

2 In Trejo I, the parties filed numerous new authority letters and stipulations to extend appellate briefing. Because an evolving theory of federal preemption (impossibility preemption) was at issue, the court required additional briefing from the parties. (See Trejo I, supra, at pp. 149–152 [noting development of nationwide caselaw applying impossibility preemption to over-the-counter medications].) In a post- remand motion filed in November 2020, Trejo’s counsel acknowledged briefing on the preemption issue was necessitated by the United States Supreme Court’s decision in Mutual Pharmaceutical Company, Inc., v. Bartlett (2013) 570 U.S. 472, “which was decided a few months after briefing on the appeal was completed on February 13, 2013.”

3 B. The Initial Retrial Deadline and Proceedings on Remand The remittitur was filed in the trial court on October 20, 2017. From this date, Trejo had three years to bring the matter to retrial. (Code Civ. Proc., § 583.320, subd. (a)(3).) Due to the COVID-19 pandemic, the deadline was initially extended by six months to April 20, 2021. (See Cal. Rules of Court, Appen. I, Emergency Rule 10(b).)3 The parties submitted (re)trial setting briefs in April 2018. To permit additional discovery, Johnson & Johnson requested a retrial date in September 2018. Represented by lead counsel and several other attorneys throughout the underlying proceedings, Trejo estimated trial would take “at least 23–27 court days” and include “approximately 15–20 witnesses,” making it a long-cause trial. (See Super. Ct. L.A. County, Local Rules, rule 2.8(e) [long- cause trial covers “20 or more days of testimony”].) One year later (April 2019), Trejo designated 11 non- retained expert witnesses and 17 retained expert witnesses. The following month, the parties stipulated to complete all fact witness and expert depositions, pretrial motions, and long-cause package submissions no later than August 29, 2019. Throughout 2019 and 2020, Johnson & Johnson requested Trejo’s portions of exhibit and witness lists and proposed statements of the case. In November 2020, Trejo filed a motion

3 “Notwithstanding any other law, including Code of Civil Procedure section 583.320, for all civil actions filed on or before April 6, 2020, if a new trial is granted in the action, the three years provided in section 583.320 in which the action must again be brought to trial is extended by six months for a total time of three years and six months.” (Cal. Rules of Court, Appen. I, Emergency Rule 10(b).)

4 for trial preference that was denied as premature. Trejo did not refile or otherwise renew his request for trial preference. On May 17, 2021, the parties filed their notice of submission for long-cause determination.4 The court rejected the submission as deficient because (1) the joint witness list suggested some witnesses would “possibly” be called to testify; (2) the joint exhibit list “reserve[d] several exhibits” for later use by Trejo; and (3) the package did not include jury instructions or special verdicts. The court found the matter not ready for trial. Between April 2019 and August 2021, Trejo served 18 new or revised reports from one designated expert (Dr. Soller) and three new reports from other experts (Drs. Alessi, Bamshad, and Sherman). Johnson & Johnson deposed (and in some instances, re-deposed) these experts between February 2020 and November 2021.

C. Order to Show Cause re Dismissal and the Extended Deadline In October 2021, the court found a resubmitted long-cause trial package deficient and declined to refer the matter for trial “because the action appears to be subject to mandatory dismissal” under the limitations statutes (§§ 538.320 et seq.). The court issued an order to show cause re dismissal and scheduled a hearing for November 5, 2021. Following briefing and a hearing, the court found it impossible, impracticable, or futile to bring the case to retrial by April 2021 due to the “unavailability of courtrooms in Los

4 In subsequent briefing, Trejo’s counsel recognized his delayed production of exhibits and an exhibit list, as well as “various deficiencies” in his long cause documents.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hartman v. Santamarina
639 P.2d 979 (California Supreme Court, 1982)
Walker v. Superior Court
807 P.2d 418 (California Supreme Court, 1991)
Central Mutual Ins. v. Executive Motor Home Sales, Inc.
143 Cal. App. 3d 791 (California Court of Appeal, 1983)
Wilcox v. Ford
206 Cal. App. 3d 1170 (California Court of Appeal, 1988)
Chin v. Meier
235 Cal. App. 3d 1473 (California Court of Appeal, 1991)
Karubian v. Security Pacific National Bank
152 Cal. App. 3d 134 (California Court of Appeal, 1984)
Hoffman v. State of California
171 Cal. App. 3d 1100 (California Court of Appeal, 1985)
Lemaire, Faunce & Katznelson v. Cox
171 Cal. App. 3d 297 (California Court of Appeal, 1985)
Monzon v. Schaefer Ambulance Service, Inc.
224 Cal. App. 3d 16 (California Court of Appeal, 1990)
Standard Oil Co. of California v. Superior Court
61 Cal. App. 3d 852 (California Court of Appeal, 1976)
Lakkees v. Superior Court
222 Cal. App. 3d 531 (California Court of Appeal, 1990)
Nail v. Osterholm
13 Cal. App. 3d 682 (California Court of Appeal, 1970)
Messih v. Levine
228 Cal. App. 3d 454 (California Court of Appeal, 1991)
Wilshire Bundy Corp. v. Auerbach
228 Cal. App. 3d 1280 (California Court of Appeal, 1991)
Taylor v. Hayes
199 Cal. App. 3d 1407 (California Court of Appeal, 1987)
Tamburina v. Combined Insurance Co. of America
54 Cal. Rptr. 3d 175 (California Court of Appeal, 2007)
Dae Sung Lee v. Moo Yeol Park
43 Cal. App. 4th 305 (California Court of Appeal, 1996)
Perez v. Grajales
169 Cal. App. 4th 580 (California Court of Appeal, 2008)
Cohill v. Nationwide Auto Service
16 Cal. App. 4th 696 (California Court of Appeal, 1993)
Sagi Plumbing v. Chartered Construction Corp.
19 Cal. Rptr. 3d 835 (California Court of Appeal, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Trejo v. Johnson & Johnson Consumer CA2/4, Counsel Stack Legal Research, https://law.counselstack.com/opinion/trejo-v-johnson-johnson-consumer-ca24-calctapp-2025.